Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: A randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)Francisco Hernández‐Bernal, Verena L. Muzio‐González, Rossana Remedios-Reyes et al.|EClinicalMedicine|2022Cited by 69
An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Glay Chinea-Santiago et al.|New Biotechnology|2022Cited by 58
Cuban Abdala vaccine: Effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; A cohort studyPedro I. Más-Bermejo, Marta Ayala‐Ávila, Félix O. Dickinson-Meneses et al.|The Lancet Regional Health - Americas|2022Cited by 35
Cuban Abdala Vaccine: Effectiveness in Preventing Severe Disease and Death from COVID-19 in Havana, Cuba; a Cohort StudyPedro Inocencio Más-Bermejo, Marta Ayala‐Ávila, Felix Orlando Dickinson-Meneses et al.|SSRN Electronic Journal|2022Cited by 23
The SARS-CoV-2 receptor-binding domain expressed in Pichia pastoris as a candidate vaccine antigenMiladys Limonta‐Fernández, Gerardo Guillén, Glay Chinea-Santiago et al.|medRxiv|2021Cited by 19